Difference between revisions of "Part:BBa K4165153"
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K4165153 short</partinfo>
 
<partinfo>BBa_K4165153 short</partinfo>
  
−
Tau binding peptide targeting the PHF* seed of Tau
+
A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.
  
 
===Usage and Biology===
 
===Usage and Biology===
  
−
WMW is a peptide with amino acid sequence of DVWMWNKKRK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. WMW can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates.
+
WMW is a peptide with amino acid sequence of DVWMWNKKRK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is one of the sites that derive tau aggregation. WMW can bind to PHF* in a way that can disrupt the interaction between each PHF* and consequently reduce the aggregates.
  
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
Line 15: Line 15:
  
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
−
WMW is modeled by Apptest and TrRosetta, best model obtained from TrRosetta.
+
WMW is modeled by Apptest and TrRosetta, the best model was obtained from trRosetta.
  
  
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmw.png" style="margin-left:200px;" alt="" width="300" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmw.png" style="margin-left:300px;" alt="" width="300" /></p>
 
</html>
 
</html>
  
Line 30: Line 30:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmw-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmw-qa.png" style="margin-left:50px;" alt="" width="800" /></p>
 
</html>
 
</html>
  

Latest revision as of 14:50, 11 October 2022


WMW

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.

Usage and Biology

WMW is a peptide with amino acid sequence of DVWMWNKKRK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is one of the sites that derive tau aggregation. WMW can bind to PHF* in a way that can disrupt the interaction between each PHF* and consequently reduce the aggregates.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

WMW is modeled by Apptest and TrRosetta, the best model was obtained from trRosetta. 


                            Figure 1.: Predicted 3D structure of Synthetic peptide WMW.


Table 1: Quality assessment parameters of WMW model.

References

1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.